CER Daily Newsfeed

Beyond the Bill: How Do We Make Medicines Affordable Without Killing Innovation?

(10/10, Karen Westaway, Claire Gillis, PharmaPhorum) comments “...The answer is not to choose between affordability and innovation, but to find balance. That requires reform on both sides of the Atlantic. In the US, that means tackling PBM opacity and expanding value-based Medicare negotiations that consider clinical benefit, comparative effectiveness, and unmet medical need. In England, it means making VPAG predictable and sustainable, while ensuring NICE’s framework accounts for the broader societal value of innovation. For both, it means ensuring that, when medicines are approved, patients can actually access them in a timely way.” Full

Video: Patti's People - Patti Peeples Speaks with Jason Shafrin

(10/10, The Evidence Base) “In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Jason Shafrin, Senior Managing Director, Center for Health Economics and Policy, FTI Consulting.” View Video

HEMA Opens Consultation on Framework for Evaluating Benefits in Health Technology Assessment

(10/10, The Evidence Base) reports “...This first report takes step to address this need by examining how HTA agencies might determine which treatment benefits are appropriate to include in economic evaluation, particularly as health systems increasingly look beyond traditional clinical outcomes. It sets out a clear framework and guiding principles to help organizations assess whether ‘novel value elements,’ such as productivity impacts, equity considerations, or patient preferences toward health risks, should be incorporated into benefit assessments.” Full

Same Time Decisions on Licensing and Value - What Pharmaceutical Companies Need to Know

(10/10, NICE Blog) comments “...Last week's webinar, 'Aligned decisions: faster patient access', attracted over 3,000 registrations and generated more than 200 questions during our interactive Q&A session, demonstrating keen interest from across the healthcare ecosystem in understanding NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) role in improving how quickly new medicines reach NHS patients in England. We're keen to build on this momentum and invite stakeholders to participate in our ongoing user research to help shape this work. In this blog, we outline key points from the webinar and discuss next steps.” Full

UK Confirms 'Landmark' Partnership With US Amid Drug Pricing Increase Rumors

(10/9, Eliza Slawther, Pink Sheet) reports “...A government spokesperson declined to comment specifically on plans to increase the thresholds, but told the Pink Sheet: ‘We've secured a landmark economic partnership with the US that includes working together on pharmaceutical exports from the UK whilst improving conditions for pharmaceutical companies here.’” Subscription Required